Undisclosed transthyretin amyloidosis therapeutic / Metagenomi - LARVOL DELTA

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones (GlobeNewswire) - "2025: Nominate one to two Development Candidates from the Wave 1 Ionis collaboration development programs and disclose remaining therapeutic indications in large cardiometabolic indications for the remaining development programs; 2026: Initiate IND-enabling activities for the Development Candidates nominated in 2025 and nominate additional Development Candidates from the remaining Wave 1 targets."

New molecule • Preclinical • Cardiovascular • Metabolic Disorders